Hemlibra

Active Ingredient(s): Emicizumab
FDA Approved: * November 16, 2017
Pharm Company: * GENENTECH INC
Category: Blood Clotting (Hemostasis)

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche).[1] A Phase I clinical trial found that it was well tolerated by healthy subjects.[2] In November 2017, it was approved in the United States for treatment of haemophilia A in those who had developed resistance to other treatments.[3] It was subsequently approved by the US FDA in April 2... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Hemlibra 30 mg/ml Subcutaneous Injection, Solution

NDC: 50242-920

Labeler:

Genentech, Inc.

Hemlibra 150 mg/ml Subcutaneous Injection, Solution

NDC: 50242-921

Labeler:

Genentech, Inc.

Hemlibra 150 mg/ml Subcutaneous Injection, Solution

NDC: 50242-922

Labeler:

Genentech, Inc.

Hemlibra 150 mg/ml Subcutaneous Injection, Solution

NDC: 50242-923

Labeler:

Genentech, Inc.

Hemlibra 12 mg/.4ml Subcutaneous Injection, Solution

NDC: 50242-927

Labeler:

Genentech, Inc.

Hemlibra 300 mg/2ml Subcutaneous Injection, Solution

NDC: 50242-930

Labeler:

Genentech, Inc.